

3rd November, 2018

To, The Manager, The BSE Limited 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Dear Sir/Madam,

Subject: Outcome of the meeting of the Board of Directors of Alembic Limited

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has:

- a) Approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2018. We enclose herewith Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter and half year ended 30th September, 2018; and
- b) On recommendation of the Audit Committee, considered and approved Composite Scheme of Arrangement ('Scheme') for the transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited ('the Company' or 'the First Demerged Company'), comprising of a real estate development project alongwith related real estate interest and Project Management Consultancy business into Shreno Limited ('the First Transferee Company' or 'the Second Demerged Company') and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited ('the Second Transferee Company') and their respective shareholders with effect from the Appointed Date i.e. 1st November 2018.

The information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with SEBI Circular no. CFD/DIL3/CIR/2017/21 dated 10th March 2017 is being filed separately.



The meeting of the Board of Directors of the Company commenced at 12 noon and concluded at 13:25 p.m.

Kindly take the above on record.

Thanking you, Yours faithfully,

For Alembic Limited

Drigesh Mittal

Company Secretary

Encl: as above



ALEMBIC LIMITED

CIN:L26100GJ1907PLC000033

Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 2280550 Fax: 0265 2282506
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2018

		Rs. in Lak						
			Quarter Ended		Half Yea	r Ended	Year Ended	
Sr. No.	Particulars	30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)	
1	Revenue from Operations	3,356	4,452	3,254	7,808	6,215	12,530	
2	Other Income	2,422	130	2,597	2,552	2,983	3,701	
3	Total Income	5,778	4,582	5,852	10,360	9,198	16,231	
4	Expenses Cost of Materials Consumed	1,806	546	1,126	2,352	1,745	3,986	
		400	1,427	769	1,827	1,410	3,078	
	Cost of Construction Changes in Inventories of Finished Goods and WIP	(596)	766	154	170	899	809	
		662	485	515	1,147	1,008	2,074	
	Employee Benefit Expenses Finance Costs	4	6	7	11	11	17	
	Depreciation and amortisation expense	56	64	112	120	236	378	
	Other Expenses	449	403	192	852	477	1,472	
	Total Expenses	2,782	3,697	2,875	6,479	5,786	11,813	
5	Profit Before Tax	2,996	885	2,976	3,881	3,412	4,417	
6	Tax Expenses							
	Current Tax	147	190	137	337	227	431	
	Deferred Tax	(86)	20	17	(67)	28	30	
	Short / (Excess) Provision of earlier years	-	(16)		(16)		(222)	
7	Net Profit after tax for the Period	2,935	691	2,822	3,627	3,157	4,178	
8	Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss	3,368	942	521	4,311	526	4,443	
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	160	(134)	(180)	27	(183)	114	
9	Total Comprehensive Income for the Period	6,464	1,500	3,163	7,964	3,500	8,735	
10	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.14	0.26	1.06	1.40	1.18	1.56	





Rs. In Lakhs

		Quarter Ended			Half Year Ended		Year Ended	
Sr.								
No.	Particulars	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Segment Revenue							
	Revenue from Operations							
	a. Active Pharmaceutical Ingredients Business	1,865	1,955	1,776	3,819	3,519		
	b. Real Estate Business	1,491	2,498	1,479	3,989	2,696		
	Total Income from Operations (Net)	3,356	4,452	3,254	7,808	6,215	12,530	
2	Segement Results (Profit (+)/ Loss (-) before Taxes and							
	interest from each segment)							
	a. Active Pharmaceutical Ingredients Business	21	99	139	119	144	26	
	b. Real Estate Business	653	727	354	1,380	517	1,319	
	Total	674	826	494	1,500	661	1,346	
	Unallocable Income and Expenditure							
	(i) Interest Expense	(4)	(6)	(7)	(11)	(11)		
	(ii) Dividend Income and Gain on financial asset at Fair Value	2,293	33	2,503	2,327	2,738	2,940	
	(iii) Other Income / (Expense)	33	32	(13)	65	24	148	
	Total Profit Before Tax	2,996	885	2,976	3,881	3,412	4,417	
3	Segment Assets							
	a. Active Pharmaceutical Ingredients Business	18,020	17,456	18,887	18,020	18,887	17,189	
	b. Real Estate Business	8,708	9,294	7,295	8,708	7,295	7,426	
	c. Unallocated	25,723	19,722	21,338	25,723	21,338	27,581	
	Total	52,451	46,473	47,520	52,451	47,520	52,196	
4	Segment Liabilities							
	a. Active Pharmaceutical Ingredients Business	3,222	2,457	2,180	3,222	2,180	2,071	
	b. Real Estate Business	4,274	4,575	4,195	4,274	4,195	4,309	
	c. Unallocated	941	1,272	1,512	941	1,512	947	
	Total	8,437	8,304	7,887	8,437	7,887	7,328	

Notes:

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The Board of Directors of the Company in their meeting held on 3rd November, 2018 have considered and accorded approval to the Composite Scheme of Arrangement between Alembic Limited, Shreno Limited and Nirayu Private Limited and their respective shareholders under section 230-232 of the Companies Act, 2013 and the rules and regulations made thereunder ("Scheme"), involving, inter alia, demerger of the Identified Real Estate Undertaking (as defined in the Scheme) of the Company into Shreno Limited w.e.f 1st November 2018, being the Appointed Date.

For Alembic Limited

Place : Vadodara

Date: 3rd November, 2018



Chirayu Amin

Statement of Standalone Assets and Liabilities		Rs. in Lakns
	As at 30th Sept,	As at 31st March,
Particulars	2018	2018
	Unaudited	Audited
	Ollauditeu	Addiced
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	13,165	13,223
(b) Investment Property	6,493	4,681
(c) Financial Assets	-,	,,
(i) Investments	19,751	15,596
(ii) Loans	9	27
(ii) Loans	39,419	33,527
	00,120	30,52.
Current Assets		
(a) Inventories	2,872	3,241
(b) Financial Assets		
(i) Investments	5,971	11,985
(ii) Trade Receivables	2,995	2,529
(iii) Cash and Cash Equivalents	134	44
(iv) Bank Balances other than (iii) above	47	37
(v) Loans	8	
(vi) Others	2	124
(c) Other Current Assets	881	576
(d) Assets held for sale	121	132
(a) Assets field for sale	13,032	18,669
	20,002	20,300
TOTAL - ASSETS	52,451	52,196
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	5,136	5,341
(b) Other Equity	38,878	39,528
(b) other equity	44,013	44,869
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Other Financial Liabilities	457	412
(b) Provisions	607	80
(c) Deferred Tax Liability (Net)	758	923
	1,822	1,415
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables		
a) Due to Micro and Small Enterprises	•	-
b) Due to other than Micro and Small Enterprises	2,954	1,642
(ii) Other Financial Liabilities	1,290	1,495
(b) Other Current Liabilities	1,116	1,686
(c) Provisions	1,073	1,065
(d) Current Tax Liabilities (Net)	183	24
	6,615	5,912
TOTAL FOLLITY AND HARMITIES	F2 4F4	F2 10C
TOTAL - EQUITY AND LIABILITIES	52,451	52,196

For Alembic Limited

Place: Vadodara

Date: 3rd November, 2018



Chirayu Amin Chairman

CNK & Associates LLP

Chartered Accountants

C - 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station,

Faramji Road, Alkapuri, Vadodara - 390 005. Ph.: +91-265-2343483, 2354353, 2354359

Email: alok@cnkindia.com • vadodara@cnkindia.com

Limited Review Report

To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Alembic Limited** ("the Company") for the quarter/half year ended 30th September, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
- 2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
- 4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, CNK & Associates LLP

Chartered Accountants

Firm Registration no. 101961W/W-100036

Alok B Shah

(Partner)

Membership No. 042005

Vadodara, 3rd November, 2018